Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment

Open access
Ariëns, L, Nimwegen, K, Shams, M, Bruin, D, Schaft, J, Os-Medendorp, H, Bruin-Weller, M · 2019 · Acta Dermato Venereologica

Abstract

Given the introduction of new therapies targeting specific immune pathways for atopic dermatitis (AD), information on the economic burden of AD patients is needed. Direct costs (medication use and healthcare resource utilization) and costs of productivity loss were studied in 90 adult patients with AD indicated for systemic treatment. Costs were calculated for patients with controlled (Investigator Global Assessment (IGA) 0-2) and uncontrolled (IGA 3-5) disease at inclusion. Mean (95% confidence interval (95% CI)) total direct costs were €5,191 (€4,382-6,019) per patient per year (PPY), €4,401 (€3,695-5,215) for patients with controlled AD vs. €6,993 (€5,552-8,406), mean difference €2,593 (€820-4,282) (p=0.014) for patients with uncontrolled AD. Costs of productivity loss were €10,040 (€6,260-14,012) PPY for the total group, €6,886 (€4,188-10,129) PPY for patients with controlled AD vs. €13,702 (€6,124-22,996) for patients with uncontrolled AD, mean difference €6,816 (-€1,638-16,677; p=0.148). Total costs (direct costs+costs of productivity loss) were €15,231 (€11,487-19,455) PPY for the total group, €11,287 (€7,974-15,436) for patients with controlled AD vs. €20,695 (€14,068-34,564), mean difference €9,408 (-€119-19,964) (p=0.077) for patients with uncontrolled AD. Patients with AD using systemic immunosuppressive treatment incur considerable direct costs and costs of productivity loss.

Overview

Integrity signals

Registry

Crossref · 10.2340/00015555-3212

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 21 references

Cited by

See all 79

Metadata

Authors
Ariëns, L., Nimwegen, K., Shams, M., Bruin, D., Schaft, J., Os-Medendorp, H., & Bruin-Weller, M.
Affiliations
  • University Medical Center Utrecht (NL)
  • Pharmerit (Netherlands) (NL)
  • Sanofi (Netherlands) (NL)
Venue
Acta Dermato Venereologica
Published
2019
Volume
99
Issue
9
Pages
762-768
ISSN
0001-5555 (ISSN-L)
OpenAlex
W2944714946
Cited by
79
References
21
Citations by year
2026: 7 · 2025: 11 · 2024: 12 · 2023: 12 · 2022: 14 · 2021: 13 · 2020: 10
FWCI
9.33
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Acta Dermato Venereologica (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Funders
  • Sanofi
  • Regeneron Pharmaceuticals
  • Sanofi Genzyme
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
Keywords
atopic dermatitis, economic burden, direct costs, productivity loss, systemic immunosuppressive therapy, disease control, healthcare resource utilization, drug costs, adults
MeSH terms
Absenteeism, Work Performance, Presenteeism, Adult, Age Factors, Dermatitis, Atopic, Dermatologic Agents, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Severity of Illness Index, Time Factors, Drug Costs, Treatment Outcome, Cost of Illness, Sick Leave

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment. https://app.cochat.ai/papers/10.2340/00015555-3212
The paper
Ariëns, L., Nimwegen, K., Shams, M., Bruin, D., Schaft, J., Os-Medendorp, H., & Bruin-Weller, M. (2019). Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment. Acta Dermato Venereologica. https://doi.org/10.2340/00015555-3212

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.